Successful treatment of mesenterial venous thrombosis with recombinant hirudin-a report of five cases

Thrombosis Research

Volumn 118, Issue 2, 2006, Pages 241-245

  Puurunen, Marja ^a   Lassila, Riitta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Hirudin; Mesenterial venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; HYDROXYUREA; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT HIRUDIN; WARFARIN;

ABDOMINAL RADIOGRAPHY; ACUTE DISEASE; ADULT; ANAMNESIS; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG SUBSTITUTION; FAMILY HISTORY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; FOLLOW UP; HETEROZYGOTE; HUMAN; INTRAVENOUS CATHETER; LONG TERM CARE; MALE; MESENTERIC VEIN THROMBOSIS; MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN S DEFICIENCY; SPLENOMEGALY; SUPERIOR MESENTERIC VEIN; THROMBOSIS PREVENTION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HIRUDINS; HUMANS; MALE; MESENTERIC VEINS; MIDDLE AGED; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 33744514506     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.06.003     Document Type: Article

References (19)

1. Jona J., Cummins Jr. G.M., Head H.B., and Govostis M.C. Recurrent primary mesenteric venous thrombosis. JAMA 227 (1974) 1033-1035
2. Rhee R.Y., Gloviczki P., Mendonca C.T., Petterson T.M., Serry R.D., Sarr M.G., et al. Mesenteric venous thrombosis: still a lethal disease in the 1990s. J Vasc Surg 20 (1994) 688-697
3. Kumar S., Sarr M.G., and Kamath P.S. Mesenteric venous thrombosis. N Engl J Med 345 (2001) 1683-1688
4. Choudhary A.M., Grayer D., Nelson A., and Roberts I. Mesenteric venous thrombosis. A diagnosis not to be missed!. J Clin Gastroenterol 3 (2000) 179-182
5. Abdu R.A., Zakhour B.J., and Dallis D.J. Mesenteric venous thrombosis-1911 to 1984. Surgery 101 (1987) 383-388
6. Harward T.R., Green D., Bergan J.J., Rizzo R.J., and Yao J.S. Mesenteric venous thrombosis. J Vasc Surgery 9 (1989) 328-333
7. al Karawi M.A., Quaiz M., Clark D., Hilali A., Mohamed A.E., and Jawdat M. Mesenteric vein thrombosis, non-invasive diagnosis and follow-up (US + MRI), and non-invasive therapy by streptokinase and anticoagulants. Hepatogastroenterology 37 (1990) 507-509
8. Robin P., Gruel Y., Lang M., Lagarrigue F., and Scotto J.M. Complete thrombolysis of mesenteric vein occlusion with recombinant tissue-type plasminogen activator. Lancet 1 (1988) 1391
9. Turitto V.T., and Weiss H.J. Red blood cells: their dual role in thrombus formation. Science 207 (1980) 541-543
10. Gordon M.B., and Beckman J.A. Successful anticoagulation with hirudin in a patient with mesenteric venous thrombosis and multiple coagulation abnormalities. Vasc Med 5 (2000) 159-162
11. Harvey R.P., Degryse E., Stefani L., Schamber F., Cazenave J.P., Courtney M., et al. Cloning and expression of cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. Proc Natl Acad Sci U S A 83 (1986) 1084-1088
12. Agnelli G., Renga C., Weitz J.I., Nenci G.G., and Hirsch J. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin. Blood 80 (1992) 960-965
13. Badimon L., Badimon J., Lassila R., Heras M., Chesebro J.H., and Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated fibrillar collagen type I at arterial flow conditions. Effects of hirudin, heparin and calcium chelation. Blood 78 (1991) 423-434
14. Siljander P., Carpen O., and Lassila R. Platelet-derived microparticles associate with fibrin during thrombosis. Blood 87 (1996) 4651-4663
15. Greinacher A., Eichler P., Lubenow N., Kwasny H., and Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 96 (2000) 846-851
16. Eriksson B.I., Ekman S., Lindbratt S., Baur M., Bach D., Torholm C., et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 79 (1997) 326-333
17. Eriksson B.I., Wille-Jorgensen P., Kalebo P., Mouret P., Rosencher N., Bosch P., et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337 (1997) 1329-1335
18. The Direct Thrombin Inhibitor Trialists' Collaborative Study Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 359 (2002) 294-302
19. Schiele F., Lindegaerde F., Eriksson H., Bassand J.P., Wallmark A., Hansson P.O., et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group. Thromb Haemost 77 (1997) 834-838